Kaipulan refers to levetiracetam, a relatively new antiepileptic drug that is currently recommended by guidelines for second-line use, primarily in adults and in children with epilepsy over the age of four. It is effective in treating both partial and generalized seizures and is generally recommended for combination therapy or add-on medications. The mechanism of the antiepileptic effect of levetiracetam is not completely clear and is different from any previous antiepileptic drug, but it has been validated in animal models and in large-scale clinical trials, which have confirmed its better therapeutic effect on epilepsy. Its advantages are that it is less likely to cause liver damage and kidney damage, and it does not cause skin rash and bone marrow suppression, nor does it cause abnormal brain development in children, nor does it cause slow reaction and affect learning and intelligence.